Compare RDY & CHRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDY | CHRD |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.2B |
| IPO Year | 2001 | 2010 |
| Metric | RDY | CHRD |
|---|---|---|
| Price | $12.22 | $143.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $16.90 | ★ $149.17 |
| AVG Volume (30 Days) | ★ 2.2M | 583.9K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | 0.52% | ★ 3.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 11.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $7.72 | $12.56 |
| Revenue Next Year | $3.50 | N/A |
| P/E Ratio | $18.67 | ★ $13.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.36 | $84.25 |
| 52 Week High | $15.67 | $157.06 |
| Indicator | RDY | CHRD |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 49.31 |
| Support Level | $12.09 | $129.88 |
| Resistance Level | $12.48 | $151.13 |
| Average True Range (ATR) | 0.18 | 4.21 |
| MACD | 0.03 | -0.85 |
| Stochastic Oscillator | 82.25 | 4.61 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.